Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study

Open access

Abstract

Objective: To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design: Scandinavian cohort study. Setting: Denmark, Norway, and Sweden, 2007-21. Participants: Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Main outcome measures: Thyroid cancer identified from nationwide cancer registers. An active-comparator new user study design was used to minimise risks of confounding and time related biases from using real world studies of drug effects. Cox regression was used to estimate hazard ratios, controlling for potential confounders with propensity score weighting. Results: The mean follow-up time was 3.9 years (standard deviation 3.5 years) in the GLP1 receptor agonist group and 5.4 years (standard deviation 3.5 years) in the DPP4 inhibitor group. 76 of 145 410 patients (incidence rate 1.33 events per 10 000 person years) treated with GLP1 receptor agonists and 184 of 291 667 patients (incidence rate 1.46 events per 10 000 person years) treated with DPP4 inhibitors developed thyroid cancer. GLP1 receptor agonist use was not associated with increased risk of thyroid cancer (hazard ratio 0.93, 95% confidence interval 0.66 to 1.31; rate difference −0.13, 95% confidence interval −0.61 to 0.36 events per 10 000 person years). The hazard ratio for medullary thyroid cancer was 1.19 (0.37 to 3.86). In the additional analysis comparing the GLP1 receptor agonist group with the SGLT2 inhibitor group, the hazard ratio for thyroid cancer was 1.16 (0.65 to 2.05). Conclusions: In this large cohort study using nationwide data from three countries, GLP1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years. In the main analysis comparing GLP1 receptor agonists with DPP4 inhibitors, the upper limit of the confidence interval was consistent with no more than a 31% increase in relative risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj-2023-078225

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart of inclusion in study cohort. *Patients could be excluded for more than one reason. †Defined as no specialist care contact or use of any prescription drug. ‡Patients with a propensity score outside the overlapping common distribution of the two groups and the highest 1% and lowest 1% of the common propensity score distribution were excluded (trimming). DPP4=dipeptidyl peptidase 4; GLP1=glucagon-like peptide 1
Fig 1 Flowchart of inclusion in study cohort. *Patients could be excluded for more than one reason. †Defined as no specialist care contact or use of any prescription drug. ‡Patients with a propensity score outside the overlapping common distribution of the two groups and the highest 1% and lowest 1% of the common propensity score distribution were excluded (trimming). DPP4=dipeptidyl peptidase 4; GLP1=glucagon-like peptide 1CC BY · PubMed Central
Fig 2 Cumulative incidence of thyroid cancer. The cumulative incidence curve and hazard ratio were adjusted for all variables shown in table 1 using propensity score fine stratification weighting. The cumulative incidence curve was truncated at 10 years because of decreasing numbers of participants and outcome events; maximum follow-up was 14.6 years. CI=95% confidence interval; DPP4=dipeptidyl peptidase 4; GLP1=glucagon-like peptide 1
Fig 2 Cumulative incidence of thyroid cancer. The cumulative incidence curve and hazard ratio were adjusted for all variables shown in table 1 using propensity score fine stratification weighting. The cumulative incidence curve was truncated at 10 years because of decreasing numbers of participants and outcome events; maximum follow-up was 14.6 years. CI=95% confidence interval; DPP4=dipeptidyl peptidase 4; GLP1=glucagon-like peptide 1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 167

Metadata

Authors
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P.
Affiliations
  • Statens Serum Institut (DK)
  • Karolinska Institutet (SE)
  • Sahlgrenska University Hospital (SE)
  • The Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden
  • Norwegian University of Science and Technology (NO)
  • University of Copenhagen (DK)
Corresponding author
Pasternak, Björn
Venue
BMJ
Publisher
BMJ
Published
2024-04-10
Volume
385
Pages
e078225
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4394707684
Cited by
125
References
24
Citations by year
2026: 47 · 2025: 58 · 2024: 20
FWCI
41.17
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Vetenskapsrådet
  • Karolinska Institutet
  • Novo Nordisk Fonden
  • Cancerfonden
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
GLP-1 receptor agonists, thyroid cancer, medullary thyroid carcinoma, DPP-4 inhibitors, SGLT2 inhibitors, drug safety, cancer risk, type 2 diabetes treatment, propensity score weighting
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Denmark, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Norway, Risk Factors, Scandinavian and Nordic Countries, Sweden, Thyroid Neoplasms, Cohort Studies, Incidence, Proportional Hazards Models, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. https://app.cochat.ai/papers/10.1136/bmj-2023-078225
The paper
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024). Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. https://doi.org/10.1136/bmj-2023-078225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.